Movement Alert|Spyre Therapeutics Rises 5.02% in Regular Trading, Trading at $93.51

Market Focus
07/08

On July 8, Spyre Therapeutics rose 5.02% in regular trading, trading at $93.51 USD/share, with Turnover of $39.24 million.

Within the Biotechnology sector where Spyre Therapeutics belongs, the overall sector performance was mixed. Among individual stocks, Vertex Pharmaceuticals down 1.12%, AbbVie up 0.96%, Gilead Sciences up 3.69%, Moderna down 3.30%, Amgen up 0.43%.

Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation inflammatory bowel disease products through best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Its pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10